Showing 131-140 of 9661 results for "".
- Global Study Maps Wide Disparities in Access to Dermatologic Carehttps://practicaldermatology.com/news/global-study-maps-wide-disparities-in-access-to-dermatologic-care/2488213/A global analysis of dermatologic care found substantial disparities in dermatologist availability, training opportunities, and access to specialty services, with lower-resource countries facing the greatest gaps. The cross-sectional study surveyed dermatology leaders across World Health O
- Hidradenitis Suppurativa Linked to Higher Cardiovascular Risk: Meta-Analysishttps://practicaldermatology.com/news/hidradenitis-suppurativa-linked-to-higher-cardiovascular-risk-meta-analysis/2488190/Hidradenitis suppurativa (HS) was associated with increased risk of multiple cardiovascular outcomes in a systematic review and meta-analysis encompassing 373,689 individuals with the chronic inflammatory skin disease. Cardiovascular Comorbidities and Hidradenitis Suppurativa
- Review Explores Energy-based Devices in Gender-affirming Carehttps://practicaldermatology.com/news/review-explores-energy-based-devices-in-gender-affirming-care/2488181/Laser and energy-based devices (EBDs) may address several dermatologic concerns relevant to transgender patients, from unwanted hair and acne to postoperative scars and body contouring, according to a recent review by Zarghami et al. Laser Applications Span Hair Removal, Acne, and Postsur
- AI-Assisted LC-OCT Detects Subclinical Basal Cell Carcinomahttps://practicaldermatology.com/news/ai-assisted-lc-oct-detects-subclinical-basal-cell-carcinoma/2488169/Artificial intelligence (AI)-assisted line-field confocal optical coherence tomography (LC-OCT) identified subclinical basal cell carcinoma (BCC) in clinically inconspicuous facial skin among patients at increased risk for BCC, according to results from a prospective cross-sectional feasibility s
- Cherry Angiomas Linked to NF1-Related Vascular Changes: Studyhttps://practicaldermatology.com/news/cherry-angiomas-linked-to-nf1-related-vascular-changes-study/2488158/Cherry angiomas may be a previously underrecognized vascular manifestation of neurofibromatosis type 1 (NF1), according to findings from a prospective comparative study in JAMA Dermatology. Investigators evaluated 259 participants (102 individuals with confirmed NF1 and 157 contro
- AbbVie Names 34 Immunology Scholarship Recipients for 2026https://practicaldermatology.com/news/abbvie-names-34-immunology-scholarship-recipients-for-2026/2488127/AbbVie has announced 34 recipients of its 2026 AbbVie Immunology Scholarship, according to a news release, marking the 10th year of a program designed to support students living with chronic inflammatory diseases as they pursue higher education. Since the scholarship launched in 2016, AbbV
- LEO Pharma Acquires Worldwide Rights to Dersimelagon for EPP, XLPhttps://practicaldermatology.com/news/leo-pharma-acquires-worldwide-rights-to-dersimelagon-for-epp-xlp/2488131/LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma, adding a late-stage investigational therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) to its rare dermatology pipeline. Under the agreement, LEO Pharma w
- AI Beauty Tools May Favor Narrower Facial Aesthetic Standards: Supplementhttps://practicaldermatology.com/news/ai-beauty-tools-may-favor-narrower-facial-aesthetic-standards-supplement/2488121/Artificial intelligence (AI) is emerging as another influence on facial aesthetic standards, potentially affecting how patients perceive attractiveness and approach cosmetic procedures, according to brief review in The Journal of Craniofacial Surgery. The authors explored how AI s
- GLP-1 Receptor Agonists Not Linked to Increased Melanoma Risk in T2Dhttps://practicaldermatology.com/news/glp-1-receptor-agonists-not-linked-to-increased-melanoma-risk-in-t2d/2488105/GLP-1 receptor agonist (GLP-1RA) therapy was not associated with an increased risk of melanoma among adults with type 2 diabetes (T2D) in a large target trial emulation published in Diabetes, Obesity and Metabolism. GLP-1RA Use and Skin Cancer Risk Investigators used TriN
- Upadacitinib Meets Primary Endpoint in Two Phase 3 Alopecia Areata Trialshttps://practicaldermatology.com/news/upadacitinib-meets-primary-endpoint-in-two-phase-3-alopecia-areata-trials/2488081/New data suggests upadacitinib was associated with significantly greater scalp hair regrowth than placebo among adults and adolescents with severe alopecia areata (AA), according to findings published online August 12 in JAMA Dermatology. The replicate UP-AA1 and UP-AA2 trials enr